Senores Pharmaceuticals is currently trading at Rs. 560.35, up by 11.80 points or 2.15% from its previous closing of Rs. 548.55 on the BSE.
The scrip opened at Rs. 564.55 and has touched a high and low of Rs. 584.10 and Rs. 556.00 respectively. So far 21492 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 644.40 on 06-Feb-2025 and a 52 week low of Rs. 440.00 on 13-Jan-2025.
Last one week high and low of the scrip stood at Rs. 584.10 and Rs. 513.00 respectively. The current market cap of the company is Rs. 2566.57 crore.
The promoters holding in the company stood at 45.76%, while Institutions and Non-Institutions held 15.74% and 38.48% respectively.
Senores Pharmaceuticals has inaugurated and commenced manufacturing activities at its greenfield Active Pharmaceutical Ingredient (API) plant located at Rajpur, Kadi, Mehsana, Gujarat. Spread across around 230,000 sq. ft. with an installed capacity of around 100 Metric Tons per Annum, this is Senores’ second API manufacturing facility, adding significantly to the existing API manufacturing capabilities.
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: